As malignant blasts are potent drivers of immunosuppression in AML [36], we next assessed the functional capacity of circulating CD8+ T cells and NK cells from 7 AML patients of Study Cohort 3 before and after depletion of CD33+ malignant blasts (Fig. 2E). The gene discussed is CD33; the disease is acute myeloid leukemia.